Trevi Therapeutics Inc (NASDAQ: TRVI) kicked off on Tuesday, down -8.13% from the previous trading day ,before settling in for the closing price of $3.13. Over the past 52 weeks, TRVI has traded in a range of $0.97-$4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -40.63%. With a float of $44.06 million, this company’s outstanding shares have now reached $68.28 million.
In an organization with 25 employees, it is important to assess its efficiency.
Trevi Therapeutics Inc (TRVI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 36.11%, while institutional ownership is 43.63%. The most recent insider transaction that took place on Oct 11 ’23, was worth 1,586. In this transaction Chief Financial Officer of this company sold 785 shares at a rate of $2.02, taking the stock ownership to the 35,901 shares. Before that another transaction happened on Sep 11 ’23, when Company’s Chief Financial Officer sold 711 for $2.20, making the entire transaction worth $1,564. This insider now owns 34,394 shares in total.
Trevi Therapeutics Inc (TRVI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.08 earnings per share (EPS), higher than consensus estimate (set at -$0.09) by $0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.63% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Take a look at Trevi Therapeutics Inc’s (TRVI) current performance indicators. Last quarter, stock had a quick ratio of 15.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.29 million. That was inferior than the volume of 0.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.36%. Additionally, its Average True Range was 0.25.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 63.04%, which indicates a significant increase from 4.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.18% in the past 14 days, which was lower than the 75.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.67, while its 200-day Moving Average is $2.05. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $3.11. Second resistance stands at $3.34. The third major resistance level sits at $3.48. If the price goes on to break the first support level at $2.74, it is likely to go to the next support level at $2.60. The third support level lies at $2.37 if the price breaches the second support level.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
The company with the Market Capitalisation of 198.60 million has total of 68,960K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -29,070 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -7,820 K.
